There’s a speed dating game of sorts happening as pharmaceutical companies that have approved cancer immunotherapies are testing their medications in combination with experimental drugs in hopes of reaching more patients.

San Diego’s Oncolytics Biotech (NASDAQ: ONCY) has been an active participant in those combination efforts, with multiple pharmaceutical companies pairing its lead drug candidate, an oncolytic virus—which can infect and kill tumor cells, according to the National Cancer Institute—called pelareorep, in tests with the drug developers’ treatments. Cancer immunotherapies have shown to be effective as a treatment for some cancers, but only in a fraction of patients.

Oncolytics, which… Read more »